Semax (30mg)

What is Semax (30mg)?

Semax (30mg) is a synthetic regulatory peptide composed of seven amino acids with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was originally derived from the ACTH(4–10) fragment but was modified to retain neuromodulatory activity without the hormonal properties of the parent peptide. In research settings, Semax is commonly investigated in studies of neuronal signaling, gene regulation, and cognitive processes. The compound is classified under brain, cognitive, and nootropic peptides used in neurobiological research.

• CAS Number: 80714-61-0
• Chemical Formula: C₃₇H₅₁N₉O₁₀S
• Molecular Weight: 813.9 g/mol

The short peptide sequence contributes to its stability and allows researchers to examine how small regulatory peptides influence neuronal activity and transcriptional pathways in experimental models. Semax has been studied in preclinical and laboratory research exploring memory processes, neurotrophin signaling, and stress-response pathways.

What are the key features of Semax (30mg)?

• Lyophilized peptide supplied in a 30 mg research vial
• High purity, commonly ≥98–99%, verified by HPLC
• Identity confirmed by mass spectrometry (MS) analysis
• Short seven-amino-acid peptide structure
• Commonly investigated in studies of neurotrophin signaling and cognitive function
• Frequently used in laboratory research involving neuronal gene expression
• For laboratory research use only

How is Semax (30mg) synthesized?

Semax is produced using solid-phase peptide synthesis (SPPS), a widely used method for assembling peptides in laboratory environments. During this process, individual amino acids are sequentially attached to a solid resin until the full peptide chain is completed. This controlled process ensures accurate construction of the peptide sequence. Once synthesis is complete, the peptide is cleaved from the resin and deprotected. Because Semax is a linear heptapeptide with no cysteine residues, no disulfide bond formation step is required. The crude peptide is purified using high-performance liquid chromatography (HPLC), and mass spectrometry confirms the correct molecular weight and structural identity. Additional quality testing may include peptide purity analysis and verification of moisture content before release as a research reagent.

What is Semax (30mg) being studied for? What are its possible benefits?

Semax has been investigated in several areas of neurobiological research. Early experimental studies examined its influence on gene expression related to neurotrophic factors, including brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). These proteins are involved in neuronal development and synaptic plasticity. Research models have also explored Semax in studies involving:

• Cognitive performance and memory processes
• Oxidative stress and neuronal protection pathways
• Brain responses to stress and ischemia models
• Monoamine signaling in the central nervous system

Possible biological effects under investigation include increased expression of neurotrophin-related genes, modulation of oxidative-stress markers, and changes in behavioral performance in animal learning tasks. These outcomes remain specific to laboratory experiments and are not confirmed therapeutic effects.

How does Semax (30mg) work in research studies?

Laboratory research suggests that Semax may act as a regulatory peptide that influences gene expression within neuronal cells. Rather than acting as a classical hormone, it appears to affect signaling pathways involved in transcription and cellular communication. In experimental brain models, Semax exposure has been associated with changes in the expression of genes linked to neuronal plasticity and neurotrophic signaling. Some studies also report shifts in markers related to oxidative balance and inflammation. These findings allow researchers to explore how short peptide fragments may influence neuronal activity and adaptive responses in the brain. Semax is therefore used as a tool compound to study mechanisms involved in neuronal signaling and cognitive-related processes.

What dosing information exists for Semax (30mg)?

Reported dosing ranges for Semax vary depending on the research model and experimental objectives. In rodent studies examining gene expression or behavioral responses, doses between 50 µg/kg and 250 µg/kg have been used in controlled laboratory conditions. Some investigations exploring neuronal signaling pathways have used intranasal or injectable administration methods in animal models. In vitro experiments often use Semax at micromolar concentrations to study cellular responses, such as transcriptional activation or oxidative stress markers. These dosing strategies are specific to the experimental systems in which they were studied. Notably, no standardized human dosing guidelines exist for Semax (30mg) as a laboratory research peptide.

How should Semax (30mg) be stored and handled?

Proper storage conditions help maintain peptide integrity and experimental consistency. Recommended guidelines include:

• Store the lyophilized peptide at ≤–20 °C for long-term stability
• Protect the vial from light and moisture
• Shelf life may reach up to 24 months under proper storage conditions
• Short-term room temperature exposure during transport is acceptable
• After reconstitution, store solutions at 2–8 °C
• Prepare aliquots to minimize repeated freeze–thaw cycles

Careful handling and accurate documentation of preparation procedures help ensure reliable research results.

Where can I read more research about Semax (30mg)?

Researchers interested in Semax can consult several scientific publications and databases:

1. Eremin KO, Kudrin VS, Saransaari P, et al. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. doi:10.1007/s11064-005-8826-8
2. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-79. doi:10.1007/s10571-009-9432-0
3. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. Published 2014 Mar 24. doi:10.1186/1471-2164-15-228

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.